In-vitro constructed method for accurately predicting medication of ovarian cancer patient

Abstract

The invention discloses an in-vitro constructed method for accurately predicting medication of an ovarian cancer patient, which comprises the following steps of: 1) constructing an ovarian cancer organ, namely culturing a purer ovarian cancer organ by using a cancer tissue obtained by the ovarian cancer patient through an operation or biopsy; and 2) high-flux drug screening test, which uses microorgans as a unit for high-flux drug sensitivity test. The in-vitro constructed method for accurately predicting the medication of the ovarian cancer patient has the advantages that the digestion timeis shortened by tissues grinding, and the digestion degree is consistent; the mild digestive juice reduces the damage of the step to cells; foccules are removed to prevent target cells from being wrapped; filtering with different pore diameters for screening required cells more accurately; immune cells are removed to obtain purer cancer cells; a self-made culture medium is more suitable for the growth of ovarian cancer organs, and the culture success rate is improved; medicine screening is carried out by taking organs as a unit, so that the response of cancer tissues in vivo after clinical medication is better simulated.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to an in vitro constructed method for accurately predicting drug use for patients with ovarian cancer. Background technique [0002] At present, there are mainly the following methods for predicting drug use in patients with ovarian cancer: [0003] 1. Tumor gene detection [0004] Potentially effective drugs are speculated based on the mutation target in the patient's gene. There are often multiple drug options for a certain mutation target, and it is impossible to lock in a specific effective drug; and clinically guide the patient based on the big data of gene sequencing of tumor patient samples Most of the targeted therapies are ineffective. The reason is that the sequencing results based on some proto-oncogenes or tumor suppressor genes cannot fully reflect the genetic background of tumor patients, resulting in low predictability of drug use for patients. [0005] 2. 2D in vitro cul...